ALK4290 (Synonyms: AKST4290) |
| Catalog No.GC62833 |
ALK4290 (AKST4290) est un inhibiteur de CCR3 puissant et actif par voie orale extrait du brevet US20130261153A1, composé de l'exemple 2, avec un Ki de 3,2 nM pour hCCR3.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1251528-23-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
ALK4290 (AKST4290) is a potent and orally actively CCR3 inhibitor extracted from patent US20130261153A1, compound Example 2, with a Ki of 3.2 nM for hCCR3[1]. ALK4290 can be used for the research of neovascular age-related macular degeneration and Parkinsonism[2][3].
[1]. NIVENS MC, et, al. Use of ccr3-inhibitors. US20130261153A1.
[2]. Samanta A, te, al. Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020. Asia Pac J Ophthalmol (Phila). May-Jun 2020; 9(3):250-259.
[3]. Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic
Average Rating: 5 (Based on Reviews and 32 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *